MFDS Approves AbbVie's Migraine Prevention Drug 'Aqupta Tablets'
On the 15th, the Ministry of Food and Drug Safety announced the approval of the imported new drug from Korea AbbVie, 'Aqupta Tablets (active ingredient Atogepant)' 10mg and 60mg, used for migraine prevention.
Aqupta selectively blocks the calcitonin gene-related peptide (CGRP) receptor, a receptor that mediates intracellular signaling related to inflammation and immune responses, thereby preventing migraines. CGRP is known as a vasodilatory neurotransmitter that causes migraine headaches along with the dilation of the middle cerebral artery.
Hot Picks Today
"I Always Made Sure to Eat Naengmyeon..." Food Poisoning Cases Surge by 28%—What's Behind the Increase?
- "There Was Such a Star Performer at SK"... The Top 2Q Earnings Surprise Missed While Watching Only Hynix
- “Told to Apply as a New Graduate Without Experience”…Samsung Employees Frustrated as Path to SK hynix Is Blocked
- Dunamu Selected as Final Winner for Police “Seized Digital Asset Custody” Project
- "If You Visit Korea, You Just Have to Buy It"...What Is This 3,000-Won Bag That Foreigners Stock Up On?
Aqupta Tablets are the first oral CGRP antagonist developed with this mechanism and were previously approved by the U.S. Food and Drug Administration (FDA) in April and the European Medicines Agency (EMA) in August. The Ministry of Food and Drug Safety stated, "Aqupta Tablets are expected to help expand the options for migraine prevention drugs for adult migraine patients."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
